{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:30:45Z","timestamp":1793601045104,"version":"4.5.0"},"reference-count":0,"publisher":"Nepal Journals Online (JOL)","issue":"2","license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nep J Oph"],"abstract":"<jats:p>Introduction: Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm and it can originate from the conjunctiva and\/ or corneal epithelium. Since the rate of recurrence after surgical excision is high, chemotherapeutic and immunotherapeutic agents such as interferon alpha-2b (IFN \u03b1-2b) have been used for its treatment.\r\nObjective: Our objective is to describe the demographic variables of patients with OSSN treated with IFN \u03b1-2b and to describe the outcomes of its use in Mexican patients, treated between 2011 and 2017 at Instituto de Oftalmolog\u00eda Fundaci\u00f3n Conde de Valenciana.\r\nMaterials and Methods: This is a non-randomized retrospective interventional case series. We reviewed the files of patients older than 18 years, with clinical and\/or histopathological diagnosis of OSSN, treated with IFN \u03b1-2b alone or in combination with surgery, with a minimum of 6 months follow-up. We studied demographic variables, such as gender, age, eye affected and associated risks factors; we also studied the type of therapy with interferon (topical, intralesional and\/or associated with surgery), time of treatment, time of follow up, recurrences and complications.\r\nResults: A total of 39 patients were included. The mean age of diagnosis was 61 \u00b1 16 years and OSSN was more frequent in males (64.1% of cases). Most of the cases (43.6%) had no identifiable risk factors. The mean time of IFN \u03b1-2b treatment was 5 \u00b1 2 months, being higher in the intralesional group (6.5 months) than in the topical group (4.2 months). The clinical resolution with the use of IFN \u03b1-2b was evidenced between 0.5 and 10 months, being achieved in 87.1% of the patients.\r\nConclusions: The use of IFN \u03b1-2b is effective for the treatment of OSSN with a high success rate (87.1%) and a low incidence of relapse (5 cases), with no reported complications during follow up. \u00a0<\/jats:p>","DOI":"10.3126\/nepjoph.v10i2.18574","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T11:04:52Z","timestamp":1552043092000},"page":"143-150","source":"Crossref","is-referenced-by-count":5,"title":["Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans"],"prefix":"10.3126","volume":"10","author":[{"given":"\u00c1ngel","family":"Nava-Casta\u00f1eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Hern\u00e1ndez-Orgaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Garnica-Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ansart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Matus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Tovilla-Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Zuazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1670","published-online":{"date-parts":[[2018,12,31]]},"container-title":["Nepalese Journal of Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.nepjol.info\/index.php\/NEPJOPH\/article\/download\/18574\/19574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nepjol.info\/index.php\/NEPJOPH\/article\/download\/18574\/19574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:25:58Z","timestamp":1793600758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nepjol.info\/index.php\/NEPJOPH\/article\/view\/18574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,3,8]]}},"URL":"https:\/\/doi.org\/10.3126\/nepjoph.v10i2.18574","relation":{},"ISSN":["2091-0320","2072-6805"],"issn-type":[{"value":"2091-0320","type":"electronic"},{"value":"2072-6805","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,31]]}}}